ArticleThe Journal of the American Academy of Orthopaedic Surgeons2025
Orthopaedic Implant-Associated Rhabdomyosarcoma.
Article in The Journal of the American Academy of Orthopaedic Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetallic implants are widely used in orthopaedic surgery. These implants may have carcinogenic properties, but the incidence of associated malignancies appears to be low, and to date, only case reports and small case series have been reported. We describe a series of patients with soft-tissue sarcoma adjacent to orthopaedic implant.
methodsCases of soft-tissue sarcomas treated at our institution were reviewed to identify tumors arising next to orthopaedic implant. We collected diagnostic, therapeutic, surgical, and outcome data and conducted genetic testing on the implant-associated tumors and control tumors.
resultsWe identified 4 cases, all of which were high-grade sclerosing rhabdomyosarcoma. Median age at diagnosis was 50 years (range: 35 to 58 years). Three tumors were in the lower extremity following internal fixation of the tibia and/or fibula, whereas the fourth was posterior to spinal implant. Mean time from implant placement to diagnosis was 19.0 years (range: 10.9 to 24.3 years). Three patients underwent wide surgical resection, whereas one had metastatic disease at diagnosis and declined surgery. All were treated with chemotherapy and radiation. Genetic testing revealed a MYOD1 mutation in all four tumors. The tumor mutational burden and fraction of genome altered were slightly higher in the control tumors than in the implant-adjacent tumors, although the differences were not statistically significant. Median follow-up was 1.7 years (range: 0.8 to 2.6 years). Of the three patients with localized disease, two had no evidence of disease at latest follow-up and one died of unknown cause at 2.6 years. The patient with metastatic disease died of disease at 0.8 years.
conclusionsWe found no genetic differences between implant-associated and non-implant-associated rhabdomyosarcomas. Further investigation is needed to understand the contribution of metallic implants to tumorigenesis. Physicians should be aware of this diagnosis when a new mass arises in a patient with long-standing orthopaedic implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.